Value and affordability of CAR T-cell therapy in the United States

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

(2020) Tanya Siddiqi et al.   BLOOD

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

(2020) Jeremy S. Abramson et al.   BLOOD

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

(2020) Stephen J Schuster et al.   BLOOD

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures

(2019) Manxue Fu et al.   Recent Patents on Anti-Cancer Drug Discovery

Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models

(2019) Aasthaa Bansal et al.   MEDICAL DECISION MAKING

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells

(2019) Kevin A. Hay et al.   BLOOD

Evolution of CAR T-cell immunotherapy in terms of patenting activity

(2019) Björn Jürgens et al.   NATURE BIOTECHNOLOGY

A safe and potent anti-CD19 CAR T cell therapy

(2019) Zhitao Ying et al.   NATURE MEDICINE

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

(2019) John K. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

(2019) Thomas E. Delea et al.   PHARMACOECONOMICS

Competition and price among brand-name drugs in the same class: A systematic review of the evidence

(2019) Ameet Sarpatwari et al.   PLOS MEDICINE

Medical crowdfunding to access CAR T-cell therapy

(2019) Linda D Ho et al.   LANCET ONCOLOGY

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy

(2019) Julia Ruark et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Affordability Boards — The States’ New Fix for Drug Pricing

(2019) Tara Sklar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advancing Legislation on Drug Pricing — Is There a Path Forward?

(2019) Stacie B. Dusetzina et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative Approaches to Drug Pricing

(2019) So-Yeon Kang et al.   Annual Review of Public Health

Machine learning to predict 30-day quality-adjusted survival in critically ill patients with cancer

(2019) Hellen Geremias dos Santos et al.   JOURNAL OF CRITICAL CARE

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment

(2018) Pricivel M. Carrera et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Alternative payment and care-delivery models in oncology: A systematic review

(2018) Emeline M. Aviki et al.   CANCER

Financial Hardship and the Economic Effect of Childhood Cancer Survivorship

(2018) Paul C. Nathan et al.   JOURNAL OF CLINICAL ONCOLOGY

PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts

(2018) David C. Bishop et al.   MOLECULAR THERAPY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resolving the “Cost-Effective but Unaffordable” Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts

(2018) James Lomas et al.   VALUE IN HEALTH

Financial burden among older, long-term cancer survivors: Results from the LILAC study

(2018) Theresa A. Hastert et al.   Cancer Medicine

Detection of Replication Competent Lentivirus Using a qPCR Assay for VSV-G

(2018) Lindsey M. Skrdlant et al.   Molecular Therapy-Methods & Clinical Development

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

(2018) Inmaculada Hernandez et al.   JAMA Oncology

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

(2018) John K. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and Payment

(2018) Peter B. Bach   NEW ENGLAND JOURNAL OF MEDICINE

Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price

(2018) Mariángeles González-Fernández et al.   International Journal of Clinical Pharmacy

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-Cell lymphoma in the United States

(2018) Joshua A. Roth et al.   JOURNAL OF MEDICAL ECONOMICS

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court’s Recent Rulings do not Solve Fundamental Barriers to Competition

(2018) Brian K. Chen et al.   DRUGS

Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

(2018) Reith R Sarkar et al.   JNCI-Journal of the National Cancer Institute

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND

(2018) S. Hollmann et al.   VALUE IN HEALTH

Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS prodigy system

(2018) Wei Zhang et al.   Drug Design Development and Therapy

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

(2018) Melanie D. Whittington et al.   JAMA Pediatrics

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy

(2018) Melanie D. Whittington et al.   JAMA Oncology

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

(2018) Maria Castella et al.   Molecular Therapy-Methods & Clinical Development

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global Manufacturing of CAR T Cell Therapy

(2017) Bruce L. Levine et al.   Molecular Therapy-Methods & Clinical Development

Cost–effectiveness thresholds: pros and cons

(2016) Melanie Y Bertram et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

(2016) R Monjezi et al.   LEUKEMIA

The Ethics and Economics of Pharmaceutical Pricing

(2015) Sara Parker-Lue et al.   Annual Review of Pharmacology and Toxicology

Low-cost generation of Good Manufacturing Practice–grade CD19-specific chimeric antigen receptor–expressing T cells using piggyBac gene transfer and patient-derived materials

(2015) Saumya Ramanayake et al.   CYTOTHERAPY

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

(2014) A. Hill et al.   CLINICAL INFECTIOUS DISEASES

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

(2014) Peter J. Neumann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Financing cures in the United States

(2014) Anirban Basu   Expert Review of Pharmacoeconomics & Outcomes Research

Changing Physician Incentives for Affordable, Quality Cancer Care: Results of an Episode Payment Model

(2014) Lee N. Newcomer et al.   Journal of Oncology Practice

Health outcomes in economic evaluation: the QALY and utilities

(2010) S. J. Whitehead et al.   BRITISH MEDICAL BULLETIN

What Is Value in Health Care?

(2010) Michael E. Porter   NEW ENGLAND JOURNAL OF MEDICINE